fbpx Yourgene Health plc - Home
previous arrow
next arrow

Recent reports in the media from a collection of European countries suggest that there may be cause for concern with regards to the Oxford AstraZeneca COVID-19 vaccine and abnormal blood clotting. According to Norway’s medicines agency (NoMA), four new cases of “serious blood clotting in adults” have been identified following a recent review (1). Austria have suspended the use of one particular batch of the vaccine after two events, including an individual diagnosed with multiple blot clots who ultimately died 10 days after receiving the vaccine (2). Overall, more than a dozen European countries suspended their use of the AstraZeneca vaccine (3).

Following these reports, AstraZeneca issued an update on the safety data for their COVID-19 vaccine. Based on the available scientific evidence from the vaccination of over 17 million people across the European Union (EU) and UK, the company reports that there is “no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia, in any defined age group, gender, batch or in any particular country.” Reassurances have also come from The World Health Organization (WHO), who are currently undertaking their own investigation. Dr. Mariangela Simao, WHO Assistant Director-General for access to medicines and health products, commented ‘WHO is very much aligned with the position that we should continue immunization until we have clarified the causal relationship,’. The European Medicines Agency (EMA) has released a statement saying the benefits of taking the AstraZeneca-Oxford vaccine outweigh the risks of not taking it. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) said there was no evidence the vaccine had caused problems, and people should still go and get vaccinated when asked to do so.

Despite these reassurances, many will have concerns around their personal risk of a thrombotic event. The predisposition to form blood clots, a so called ‘hypercoagulable condition’, can arise from underlying genetic mutations, or acquired changes in the clotting mechanism. More commonly it is a combination of both genetic and acquired factors.  In the general population, the prevalence of an inherited thrombotic syndrome is presently estimated to be 1 individual in 2500-5000; the prevalence increases to 4% in patients with a past history of thrombosis (4). Inherited hypercoagulable conditions include:

  • Factor V Leiden mutation (G1691A/R506Q)
  • Prothrombin mutation (Factor II) (G20210A)
  • Elevated levels of homocysteine
    • MTHR (677 C>T)
    • MTHR (1298 A>C)
  • Deficiencies of natural clotting proteins e.g. protein C

A thrombophilia laboratory ‘screen’ often includes a range of tests, including both functional clotting assessments and genetic analysis. The choice of which genetic mutations to test for often depends on the ethnic admixture of the population being served and local guidelines taking into account clinical utility.

Factor V Leiden (FVL) is the most common of these heritable causes. It is caused by a single nucleotide substitution resulting in an R506Q mutation, resulting in factor V resistance to activated protein C (APC) inactivation. Heterozygosity for Factor V Leiden occurs in 3–8% of the US and European populations, and accounts for 40-50% of all cases of heritable hypercoagulable conditions (5). The lifetime risk of a clot in heterozygotes is around 10%, and this rises to 80% in homozygotes (6). The prevalence of a heterozygous G20210A prothrombin mutation is thought to be about 1.5% in the UK (7).

The ARUP laboratories testing directory (6) suggests testing for FVL should be considered in:

  • One unprovoked venous thromboembolism, particularly before age 50
  • Recurrent blood clots
  • Blood clots in unusual locations
  • Personal history of clots and one family member with clot before age 50 or two or more family members with clots
  • Individuals with low activated protein C (APC) resistance activity

These guidelines are broadly in line with those issued by NICE and the British Society for Haematology (BSH) in the UK for thrombophilia screening. However, in many countries a thrombophilia screen may also be considered in women who sadly experience recurrent miscarriage. Thrombophilia is a common cause of recurrent miscarriage, and has been reported in up to 40–50% of cases (8). Pregnancy is in and of itself an acquired form of hypercoagulable state that is exacerbated when a woman has an underlying predisposition such as FVL.

Identifying individuals with an underlying genetic predisposition is important for both understanding recurrence risk, and guiding treatment options. For example, there are specific recommendations for prophylactic use of anti-clotting agents in pregnant women with FVL. Testing can also offer reassurance for patients, or may prompt them to make lifestyle changes in light of a known inherited risk. Obesity is known to be a significant acquired risk factor for a clotting event, as is smoking and the use of some oral contraceptive pills (9).

Many trusted safety and advisory committees, including those from the EMA and the WHO, have presented compelling evidence that the benefits of the AstraZeneca vaccine still outweigh the risks despite possible a link to abnormal blood clotting events. Such events are very rare - around 20 million people in the UK/EEA have received the vaccine (as of 16/03/21) with only 25 cases presented to the EMA for review (10). An inherited predisposition to form blood clots, however, is not rare. Identifying those with an underlying predisposition is important to enable appropriate clinical decision making, and to allow individuals to make informed lifestyle choices in light of their personal risk.

At Yourgene Health we look to support our trusted laboratory partners to provide the testing services that offer most value to the patients they serve. Our Thrombophilia panel, TRP-Fplus, covers 4 of the most common mutations associated with thrombophilia:

  • Factor V Leiden (G1691A/R506Q)
  • Factor II (G20210A)
  • MTHR (677 C>T)
  • MTHR (1298 A>C)

Our assay therefore enables laboratories to provide a rapid, high-quality thrombophilia screen and identify those individuals with a predisposition to clotting events such as DVT.

  1. https://news.sky.com/story/covid-19-how-common-have-blood-clots-been-after-the-astrazeneca-jab-and-should-we-be-worried-12246472
  2. https://www.bmj.com/content/372/bmj.n699
  3. https://www.npr.org/sections/coronavirus-live-updates/2021/03/21/979781065/european-scientists-zero-in-on-astrazeneca-blood-clot-link?t=1616426581822
  4. https://www.medscape.com/answers/1086399-158333/what-is-the-prevalence-of-inherited-thrombophilia
  5. https://www.nature.com/articles/gim920112.pdf?origin=ppub#:~:text=Factor%20V%20Leiden%20is%20the,US%20and%20Euro%2D%20pean%20populations.
  6. https://ltd.aruplab.com/api/ltd/pdf/216
  7. https://www.bmj.com/bmj/section-pdf/760940?path=/bmj/349/7967/Clinical_Review.full.pdf
  8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916273/
  9. https://www.ahajournals.org/doi/full/10.1161/01.cir.0000068167.08920.f1
  10. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots
  • Ranger® Revolution - LightBench® Detect is here! - 20 June 2022 +

    Ranger® Revolution - LightBench® Detect is Here!

    The wait is over! Yourgene Health are proud to today reveal the Ranger® Revolution in the form of the LightBench® Detect; the latest addition to our Ranger® Technology portfolio. We’ve worked closely with our clinical laboratory partners to develop a size selection instrument that is optimised for improving the performance of liquid biopsy workflows, most notably non-invasive prenatal testing (NIPT). The LightBench® Detect addresses a pressing need for NIPT

    Read More
  • Collaboration to Perform: Yourgene Microdeletions Plugin Accelerator - 24 May 2022 +

    Yourgene Health is today unveiling the Yourgene Microdeletions Plugin Accelerator phase, following a successful pilot project with LifeStrands Genomics. This Accelerator represents a new era in Yourgene’s approach to delivery of NIPT testing solutions, with a focus on ‘Collaboration to Perform’. Working as a partnership, rather than the traditional laboratory/manufacturer relationship, represents a shared commitment to ensuring high-quality and performance-driven testing, ultimately delivering better outcomes for patients.

    The Plugin has been designed for use with

    Read More
  • Exclusion criteria for NIPT explained - 15 February 2022 +

    The IONA ® test is a non-invasive prenatal test (NIPT) for pregnant women which estimates the risk of a fetus having Down’s syndrome (Trisomy 21), Edwards’ syndrome (Trisomy 18) and Patau’s syndrome (Trisomy 13). The test is performed by analysing cell-free placental-fetal DNA from a maternal blood sample. The test is suitable for women who are at least 10 weeks pregnant, prior to ten weeks there is a risk that there would be insufficient placental-fetal cell

    Read More
  • International Women and Girls in Science Day 2022 +

    Here at Yourgene Health, we are very proud that a large proportion of our genomic technologies and services business, including senior leadership and laboratory managers, are powerful women. We believe it is important to showcase the impressive range of talent we are lucky to have, including our women and girls in science.

    In light of the International Day of Women and Girls in Science, we would like to place a spotlight on a few members

    Read More
  • New Year, New Regulations - 19 January 2022 +

    The ‘New Year's resolution’ is a tradition almost all of us are familiar with, in which a person resolves to accomplish a personal goal, continue good habits or change undesirable ones all with the intention of self-improvement. A study of over 800 million activity data points on the exercise platform Strava found that today, January 19th, is the most common day for a New Year’s resolution to be abandoned ( 1 ). If you are reading this

    Read More
  • Behind the scenes: Adapting diagnostic services during a pandemic - 11 November 2021 +

    The diagnostic testing business has always been dynamic and opportunistic , but nothing could have stretched the definition of these 2 words like a pandemic.

    Since the launch of Yourgene Genomic Services 6 months into this global pandemic – born from a legacy, well established NIPT service laboratory, a modest acquisition, and an unprecedented national genomic testing demand, we have vastly expanded our testing capacity by converting every spare inch of underutilised office space created by remote

    Read More
  • Overprescribing within the NHS - 02 November 2021 +

    “Good for you, good for us but is it good for everybody?”
    Overprescribing within the NHS – October 2021

    The NHS is currently the 5th largest global employer; with over 1.3m employees and receiving around 10% of the UK Government’s annual spending. It is estimated that the NHS deals with 336 million ‘patient visits’ per year, - many of whom will receive some form of at least one ‘prescription’ per visit and at a current charge in

    Read More
  • The role genomics plays in relationships - 18 August 2021 +

    According to National Today, the website dedicated to highlighting every day celebrations and holidays, August 18 th is ‘National Couple’s Day’ – a day to celebrate the important relationships in life. Whilst not an official holiday or observance in any country, the clinical team at Yourgene Health wanted to use this opportunity to reflect upon the pivotal role that genomics plays in relationships across the world.

    Earlier this year a study, published in Nature Human Behaviour,

    Read More
  • NIPT for Sex Chromosome Aneuploidies and Autosomal Aneuploidies. A Q&A with Dr Greg Fitzgibbon - 26 May 2021 +

    Yourgene Health has recently launched IONA ® Care , an advanced prenatal screening test that performs whole-genome analysis to measure the likelihood that a pregnant woman is carrying a fetus with one the most common trisomies (trisomy 21, 18 and 13), any other Autosomal Aneuploidy (AA) or a Sex Chromosome Aneuploidy (SCA). IONA ® Care is available from the Yourgene Genomic Services laboratory in Manchester, UK. The test is available as a menu, enabling pregnant women, their families

    Read More
  • COVID-19 testing and the need for regulation - 6 May 2021 +

    The COVID-19 pandemic presented huge challenges worldwide. In response to the unprecedented need for COVID-19 PCR testing, the UK government set up a new network of Lighthouse laboratories across the country to provide the required capacity for testing thousands of samples each day. These laboratories proved a vital part of the test and trace strategy but were also under immense pressure to meet their targets and, following an investigation by Panorama , it was found that

    Read More
  • Yourgene on World Creativity and Innovation Day 2021 - 21 April 2021 +

    Innovation and creativity are two pillars at the heart of technological and scientific advances. The instrumental role they play has been recognised by the United Nations (UNN), who have designated a special day to raise awareness of the importance of innovation in culture and economic growth worldwide: 21st April. World Creativity and Innovation Day (UNN) is a day to encourage people to “think outside the box”, find new perspectives which push personal growth, identify different

    Read More
  • The IONA® test recommended for twin pregnancies screening for Down’s syndrome - 7 April 2021 +

    In recent years, fertility treatments and the fact women are having babies later has made multiple births more common. In 2016, around 12,000 sets of twins and about 190 sets of triplets or more were born in the UK. That means about 1 in every 65 births in the UK today are twins, triplets or more. 1 Extensive studies have been carried out for cell-free DNA (cfDNA) testing in singleton pregnancies with sample numbers into

    Read More
  • Blood clots, inherited thrombophilia and COVID-19 - 25 March 2021 +

    Recent reports in the media from a collection of European countries suggest that there may be cause for concern with regards to the Oxford AstraZeneca COVID-19 vaccine and abnormal blood clotting. According to Norway’s medicines agency (NoMA), four new cases of “serious blood clotting in adults” have been identified following a recent review (1). Austria have suspended the use of one particular batch of the vaccine after two events, including an individual diagnosed with multiple

    Read More
  • COVID-19 strains - what are they and why do they matter? A Q&A with Dr Michael Risley - 28 January 2021 +

    The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the beginning of the global COVID-19 outbreak, the diagnostic and research community has undertaken an unprecedented effort to understand how best to manage, eradicate and prevent the disease. In recent months we have seen the rollout of ambitious vaccination schedules worldwide, as well as the strengthening of

    Read More
  • So much to be proud of! - 23 December 2020 +

    As many have already said and written, this year has been like none other. This has been especially true for conferences and exhibitions. Every year, the commercial team at Yourgene look forward to exhibiting at various conferences globally. It’s a chance to meet our partners and customers, as well as form new relationships. With the COVID-19 pandemic none of this was possible, so when we heard that the Taiwan Healthcare Expo was still going ahead,

    Read More
  • 1
  • 2